Compare Cytokinetics Inc (CYTK) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Yum! Brands, Inc. — how do they compare? Cytokinetics Inc trades at $81.69 (market cap $11.12B), while Yum! Brands, Inc. trades at $154.87 (market cap $43.60B). The key difference: Yum! Brands, Inc. is far larger — about 3.9× Cytokinetics Inc's market cap, and Yum! Brands, Inc. pays a 1.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | YUM | |
|---|---|---|
Market Cap | $11.12B | $43.60B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $168.16 |
52-Week Low | $33.23 | $138.21 |
Enterprise Value | $11.59B | $54.86B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
YUM Brands trades at $161.69, down 1.13% today, with a bullish technical signal from moving averages and key resistance at $163. The company reported Q1 2026 EPS of $1.50, beating expectations, while revenue grew to $8.21B in 2025. Recent news includes a Taco Bell health investigation and the $2.7B Pizza Hut sale, which may streamline operations.
YUM's outlook is supported by strong cash flow and margin stability, but high debt and competitive pressures pose risks. Analysts maintain a $174.60 price target with a mixed buy/hold consensus. The stock offers growth potential post-Pizza Hut divestiture, though investor sentiment is cautious amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
